02633.HK
Jacobson Pharma Corporation Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 1.05
+2.44%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.1B | 1.6B | 1.6B | 1.5B | 1.8B |
| Cost of Revenue | 1.8B | 891.6M | 884.0M | 847.3M | 1.0B |
| Gross Profit | 1.4B | 677.9M | 692.9M | 620.5M | 747.2M |
| Operating Expenses | |||||
| R&D Expense | — | 115.0K | — | — | 1.2M |
| SG&A Expense | 649.0M | 324.6M | 324.2M | 332.4M | 426.9M |
| General & Admin Expense | 307.8M | — | 200.3M | 203.7M | 231.3M |
| Selling & Marketing Expense | 185.5M | — | 124.0M | 128.7M | 196.7M |
| Other Expenses | (24.1M) | — | (45.9M) | (45.0M) | — |
| Total Operating Expenses | 624.8M | 324.7M | 278.3M | 287.3M | 428.1M |
| Cost and Expenses | 2.4B | 1.2B | 1.2B | 1.1B | 1.5B |
| Operating Income (EBIT) | 746.0M | 353.2M | 414.6M | 333.1M | 319.1M |
| Non-Operating | |||||
| Interest Income | 23.0M | 8.3M | 14.7M | 24.0M | 17.9M |
| Interest Expense | 72.1M | 30.7M | 41.4M | 78.7M | 61.4M |
| Net Interest Income | (47.0M) | (22.4M) | (26.7M) | (54.7M) | (43.5M) |
| Other Non-Op Income/Expense | (9.9M) | 9.4M | (41.0M) | (78.5M) | (63.0M) |
| Non-Operating Income (excl Interest) | (43.6M) | — | (398.0K) | (165.0K) | (41.7M) |
| EBT (Pre-Tax Income) | 736.1M | 362.6M | 373.6M | 254.6M | 343.3M |
| Income Tax Expense | 133.8M | 61.0M | 72.8M | 44.4M | 56.5M |
| Bottom Line | |||||
| Net Income | 602.5M | 301.6M | 300.8M | 267.0M | 251.0M |
| Earnings from Cont. Ops | 602.3M | 301.6M | 300.8M | 210.2M | 207.4M |
| Earnings from Discont. Ops | — | — | — | 80.6M | 43.5M |
| Bottom Line Net Income | 602.5M | 301.6M | 300.8M | 267.0M | 251.0M |
| Per Share | |||||
| Basic EPS | HK$0.30 | HK$0.15 | HK$0.15 | HK$0.07 | HK$0.13 |
| Diluted EPS | HK$0.30 | HK$0.15 | HK$0.15 | HK$0.10 | HK$0.13 |
| Revenue Per Share | HK$1.57 | HK$0.79 | HK$0.79 | HK$0.76 | HK$0.93 |
| Shares | |||||
| Basic Shares Outstanding | 2.0B | 2.0B | 2.0B | 1.9B | 1.9B |
| Diluted Shares Outstanding | 2.0B | 2.0B | 2.0B | 1.9B | 1.9B |
| Profitability Metrics | |||||
| EBITDA | 1.1B | 507.0M | 558.9M | 475.1M | 462.0M |
| D&A | 262.5M | 153.8M | 143.9M | 141.8M | 148.7M |
| EBIT | 789.6M | 353.2M | 415.0M | 333.3M | 313.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026